FMW0 Stock Chart & Stats
€3.44
€0.00(0.00%)
At close: 4:00 PM EDT
€3.44
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.30 - €3.44
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€38.76M
Enterprise Value€49.04
Total Cash (Recent Filing)€23.88M
Total Debt (Recent Filing)€2.68M
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Nov 26, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding17,050,320
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)3.04
Price to Sales (P/S)0.00
P/FCF Ratio-1.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.89
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical De‑riskingFull enrollment of PLATEAU (239 patients) and defined interim/final readouts materially de-risk the program timeline. Reliable enrollment validates operational execution, enables near‑term binary clinical milestones that can change the development and partnering trajectory over the next 6–12 months.
Strategic CollaborationNovo Nordisk supplying Wegovy reduces trial cost and operational risk, secures high‑quality GLP‑1 supply and provides strategic validation from an incumbent. This structural partnership improves trial feasibility and creates a potential commercial pathway and credibility with payors and partners.
Patent ProtectionA U.S. notice of allowance through at least 2044 (with potential to 2046) establishes a long‑dated exclusivity window for enobosarm combinations. Meaningful patent life supports a durable commercial moat and enhances partner interest if clinical results confirm differentiated tissue‑selective benefits.
Bears Say
No Recent RevenueRevenue absence in 2025 and TTM means the company currently lacks product cash inflows to fund operations. Combined with persistent net losses, this structural lack of commercial revenue elevates execution risk and increases the need for external financing or partnership monetization to sustain development.
Cash Burn & Financing RelianceOngoing negative operating cash flow and recent reliance on an underwritten offering and ATM capacity indicate funding is dependent on capital markets. Continued burn increases dilution risk and could constrain R&D depth or timelines if capital access tightens before pivotal data readouts.
Competitive HeadwindsMarket incumbents' high efficacy sets a high commercial bar. Enobosarm's value hinges on demonstrating tissue‑selective muscle preservation and clinically meaningful weight outcomes; absent clear differentiation, payor coverage and physician adoption risk being limited versus established GLP‑1 therapies.
Veru News
FMW0 FAQ
What was Veru’s price range in the past 12 months?
Veru lowest stock price was €3.30 and its highest was €3.44 in the past 12 months.
What is Veru’s market cap?
Veru’s market cap is €38.76M.
When is Veru’s upcoming earnings report date?
Veru’s upcoming earnings report date is Nov 26, 2026 which is in 79 days.
How were Veru’s earnings last quarter?
Veru released its earnings results on Aug 10, 2026. The company reported -€0.26 earnings per share for the quarter, beating the consensus estimate of -€0.277 by €0.017.
Is Veru overvalued?
According to Wall Street analysts Veru’s price is currently Overvalued.
Does Veru pay dividends?
Veru does not currently pay dividends.
What is Veru’s EPS estimate?
Veru’s EPS estimate is -0.28.
How many shares outstanding does Veru have?
Veru has 17,050,320 shares outstanding.
What happened to Veru’s price movement after its last earnings report?
Veru reported an EPS of -€0.26 in its last earnings report, beating expectations of -€0.277. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Veru?
Currently, no hedge funds are holding shares in DE:FMW0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veru Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
35.48%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Veru
Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.
FMW0 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed multiple meaningful positive developments: full enrollment of the Phase IIb PLATEAU study with an upcoming interim analysis, demonstration of muscle-preserving benefits in the prior QUALITY study, a strategic Novo Nordisk supply agreement, a notice of allowance for a key U.S. method-of-use patent (extending protection into the 2040s), improved cash and working capital driven by a financing and realizations, and year-to-date reductions in net loss and operating cash burn. Offsetting these positives are continued net losses, ongoing negative operating cash flow, a near-term increase in R&D spend tied to PLATEAU, strong competitive pressures from established GLP-1 players, and some commercial constraint from Novo's right of first negotiation. On balance, the company showed clear progress on clinical, IP and financing fronts sufficient to fund near-term milestones, but it continues to face execution, clinical and competitive risks.View all DE:FMW0 earnings summariesTechnical Analysis
Karyopharm Therapeutics
―
Cue Biopharma
―
Inmune Bio
―
Celularity
―
Jupiter Neurosciences, Inc.
―